These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 22375487

  • 1. Clinical evaluation of the safety and immunogenicity of H5N1 pandemic influenza vaccines.
    Leroux-Roels I.
    Bull Mem Acad R Med Belg; 2011; 166(1-2):18-24. PubMed ID: 22375487
    [No Abstract] [Full Text] [Related]

  • 2. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
    Thongcharoen P, Auewarakul P, Hutagalung Y, Ong G, Gillard P, Drame M, Bock HL.
    J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672
    [Abstract] [Full Text] [Related]

  • 3. [Pandemic vaccines].
    Floret D.
    Arch Pediatr; 2010 Jun; 17(6):906-7. PubMed ID: 20654954
    [No Abstract] [Full Text] [Related]

  • 4. Influenza: options to improve pandemic preparation.
    Rappuoli R, Dormitzer PR.
    Science; 2012 Jun 22; 336(6088):1531-3. PubMed ID: 22723412
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN.
    Vaccine; 2010 Dec 16; 29(2):166-73. PubMed ID: 21055500
    [Abstract] [Full Text] [Related]

  • 6. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

  • 7. DNA-based influenza vaccines: evaluating their potential to provide universal protection.
    Choo AY, Broderick KE, Kim JJ, Sardesai NY.
    IDrugs; 2010 Oct 15; 13(10):707-12. PubMed ID: 20878593
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.
    Vaccine; 2009 Dec 30; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [Abstract] [Full Text] [Related]

  • 9. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z.
    Expert Rev Vaccines; 2009 May 30; 8(5):619-24. PubMed ID: 19397418
    [Abstract] [Full Text] [Related]

  • 10. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T, Kawaoka Y.
    Trends Mol Med; 2006 Nov 30; 12(11):506-14. PubMed ID: 17011235
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection.
    Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K, Tochihara S, Itamura S, Odagiri T, Tashiro M, Okada K, Miyazaki C, Ueda K.
    Microbiol Immunol; 2010 Feb 30; 54(2):81-8. PubMed ID: 20377741
    [Abstract] [Full Text] [Related]

  • 12. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L.
    J Infect Dis; 2010 Jun 01; 201(11):1644-53. PubMed ID: 20423222
    [Abstract] [Full Text] [Related]

  • 13. Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.
    Girard M, Palkonyay L, Kieny MP.
    Vaccine; 2008 Sep 15; 26(39):4975-7. PubMed ID: 18514979
    [No Abstract] [Full Text] [Related]

  • 14. Development of vaccines against influenza A virus (H5N1).
    Li WC, Huang YC.
    Chang Gung Med J; 2007 Sep 15; 30(4):294-304. PubMed ID: 17939259
    [Abstract] [Full Text] [Related]

  • 15. Pre-pandemic and pandemic influenza vaccines.
    Rockman S, Brown L.
    Hum Vaccin; 2010 Oct 15; 6(10):792-801. PubMed ID: 20935469
    [Abstract] [Full Text] [Related]

  • 16. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P, Launay O.
    Med Sci (Paris); 2009 Oct 15; 25(8-9):719-25. PubMed ID: 19765386
    [Abstract] [Full Text] [Related]

  • 17. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.
    Sci Transl Med; 2010 Jan 20; 2(15):15ra5. PubMed ID: 20371470
    [Abstract] [Full Text] [Related]

  • 18. Pandemic influenza vaccine development: time is of the essence.
    Cox RJ, Brokstad KA, Haaheim LR.
    Expert Rev Vaccines; 2006 Oct 20; 5(5):603-6. PubMed ID: 17181432
    [No Abstract] [Full Text] [Related]

  • 19. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 20. Pandemic influenza vaccine: the US government is not doing enough.
    Osterholm MT.
    Clin Pharmacol Ther; 2007 Dec 08; 82(6):635-7. PubMed ID: 17998909
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.